ArticleScientific reports2025
Detection of PEG-specific antibodies in SARS-CoV-2 positive and negative sera with implications for autoimmune reactivity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reported safety events from ultrasound enhancing agents: a critical reappraisal.Echo research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyethylene glycol (PEG) is a stabilizing polymer that may act as an immunogen, as some individuals produce antibodies against it and its covalent attachment to active proteins. We wanted to determine if different titers of PEG antibodies are detected in sera from subjects before and after the SARS-CoV-2 pandemic peak, and if these antibodies possibly contribute to autoimmunity. Using ELISA, we measured IgG, IgM, IgA and IgE antibodies against different sizes of PEG, Moderna COVID-19 vaccine ingredients, and phosphatidylcholine in sera from 90 healthy adults purchased in 2018 that were negative for SARS-CoV-2 IgG antibody, and sera from 90 blood donors purchased in 2023 (collected mid-August 2023) that tested positive for SARS-CoV-2 IgG. To find possible reactivity with human tissue, we also applied both polyclonal and monoclonal antibodies raised in mouse/rabbit specifically against PEG-5K to 65 different human tissue antigens. Analysis of data showed that at 3SD above the mean of the negative control, significant elevations in IgG and IgM antibodies were detected against different sizes of PEG, vaccine ingredients, and phosphatidylcholine. For IgE, significant elevations were found in the PEG-specific antibodies. For IgA antibodies, significant elevation was found only against phosphatidylcholine. The application of monoclonal and polyclonal antibodies made against PEG to 65 different human tissue antigens showed reactions with 20 out of 65 different antigens for rabbit polyclonal, 7 out of 65 for rabbit monoclonal, and 6 out of 65 for mouse monoclonal anti-PEG antibody. Administration of PEGylated products may result in the production of PEG-specific antibodies that may contribute to autoimmunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.